Limits...
Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.

Ye X, Jiang F, Li Y, Mu J, Si L, Wang X, Ning S, Li Z - Cancer Sci. (2014)

Bottom Line: However, little is known regarding the effect of microRNA (miRNA) on GLA's anti-metastatic activity.GLA induced the mesenchymal-epithelial transition in vitro and in vivo, as determined by increased expression of the epithelial marker, E-cadherin, and decreased expression of the mesenchymal marker, vimentin.Overexpression of miR-200c enhanced the expression of E-cadherin and decreased the expression of vimentin.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Modern Toxicology, Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Nanjing Medical University, Nanjing, China.

Show MeSH

Related in: MedlinePlus

Glabridin (GLA) attenuates the invasive capacities of MDA-MB-231 and BT-549 cells. The migratory and invasive capacities of MDA-MB-231 and BT-549 cells were quantified by 24-well cell migration assays and by use of the BD Matrigel tumor invasion system. Cells were exposed to 0.0, 5.0, 10.0, or 20.0 μM GLA for 48 h. Epidermal growth factor (EGF) functioned as a chemoattractant for cancer migration and invasion. GLA reduced the migratory and invasive capacities of (a, top) MDA-MB-231 and (a, bottom) BT-549 cells. (b) Numbers of migrating/invading MDA-MB-231 cells treated with GLA. (c) Numbers of migrating/invading BT-549 cells treated with GLA (mean ± SD, n = 5).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317926&req=5

fig02: Glabridin (GLA) attenuates the invasive capacities of MDA-MB-231 and BT-549 cells. The migratory and invasive capacities of MDA-MB-231 and BT-549 cells were quantified by 24-well cell migration assays and by use of the BD Matrigel tumor invasion system. Cells were exposed to 0.0, 5.0, 10.0, or 20.0 μM GLA for 48 h. Epidermal growth factor (EGF) functioned as a chemoattractant for cancer migration and invasion. GLA reduced the migratory and invasive capacities of (a, top) MDA-MB-231 and (a, bottom) BT-549 cells. (b) Numbers of migrating/invading MDA-MB-231 cells treated with GLA. (c) Numbers of migrating/invading BT-549 cells treated with GLA (mean ± SD, n = 5).

Mentions: Glabridin (GLA) did not appreciably affect the vitality of MDA-MB-231 or BT-549 breast cancer cells at concentrations of 0.0, 5.0, 10.0 or 20.0 μM (Fig. 1a). To determine the effects of GLA on the motility of breast cancer cells, wound healing assays were performed. MDA-MB-231 and BT-549 cells displayed high motility, but GLA reduced such capability in a dose-dependent manner (Fig. 1b). Because 10.0 μM GLA effectively decreased the motility of these cells, this concentration was selected for further investigations. As determined with transwell assays, GLA decreased both the migratory and invasive capacities of MDA-MB-231 and BT-549 cells (Fig. 2a–c).


Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.

Ye X, Jiang F, Li Y, Mu J, Si L, Wang X, Ning S, Li Z - Cancer Sci. (2014)

Glabridin (GLA) attenuates the invasive capacities of MDA-MB-231 and BT-549 cells. The migratory and invasive capacities of MDA-MB-231 and BT-549 cells were quantified by 24-well cell migration assays and by use of the BD Matrigel tumor invasion system. Cells were exposed to 0.0, 5.0, 10.0, or 20.0 μM GLA for 48 h. Epidermal growth factor (EGF) functioned as a chemoattractant for cancer migration and invasion. GLA reduced the migratory and invasive capacities of (a, top) MDA-MB-231 and (a, bottom) BT-549 cells. (b) Numbers of migrating/invading MDA-MB-231 cells treated with GLA. (c) Numbers of migrating/invading BT-549 cells treated with GLA (mean ± SD, n = 5).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317926&req=5

fig02: Glabridin (GLA) attenuates the invasive capacities of MDA-MB-231 and BT-549 cells. The migratory and invasive capacities of MDA-MB-231 and BT-549 cells were quantified by 24-well cell migration assays and by use of the BD Matrigel tumor invasion system. Cells were exposed to 0.0, 5.0, 10.0, or 20.0 μM GLA for 48 h. Epidermal growth factor (EGF) functioned as a chemoattractant for cancer migration and invasion. GLA reduced the migratory and invasive capacities of (a, top) MDA-MB-231 and (a, bottom) BT-549 cells. (b) Numbers of migrating/invading MDA-MB-231 cells treated with GLA. (c) Numbers of migrating/invading BT-549 cells treated with GLA (mean ± SD, n = 5).
Mentions: Glabridin (GLA) did not appreciably affect the vitality of MDA-MB-231 or BT-549 breast cancer cells at concentrations of 0.0, 5.0, 10.0 or 20.0 μM (Fig. 1a). To determine the effects of GLA on the motility of breast cancer cells, wound healing assays were performed. MDA-MB-231 and BT-549 cells displayed high motility, but GLA reduced such capability in a dose-dependent manner (Fig. 1b). Because 10.0 μM GLA effectively decreased the motility of these cells, this concentration was selected for further investigations. As determined with transwell assays, GLA decreased both the migratory and invasive capacities of MDA-MB-231 and BT-549 cells (Fig. 2a–c).

Bottom Line: However, little is known regarding the effect of microRNA (miRNA) on GLA's anti-metastatic activity.GLA induced the mesenchymal-epithelial transition in vitro and in vivo, as determined by increased expression of the epithelial marker, E-cadherin, and decreased expression of the mesenchymal marker, vimentin.Overexpression of miR-200c enhanced the expression of E-cadherin and decreased the expression of vimentin.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Modern Toxicology, Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Nanjing Medical University, Nanjing, China.

Show MeSH
Related in: MedlinePlus